Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En klinisk prövning av KVA12123-behandling ensam och i kombination med Pembrolizumab i avancerade solida tumörer (VISTA-101)

30 september 2026 uppdaterad av: Kineta Inc.

A Phase 1/2 Open-label Trial of KVA12123 [TBS-2025] Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors. The study included dose escalation and planned dose expansion phases. Only the dose escalation phases were conducted. The planned dose expansion phase were not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern.

The study sought to assess the safety of KVA12123 [TBS-2025] given alone or with pembrolizumab and to identify appropriate doses for future clinical trials. Participants in the doses for future clinical trials. Participants in the dose escalation phases visited study sites for treatment and safety assessments. These assessments included blood samples, imaging scans, physical examinations, and heart function tests.

Studieöversikt

Detaljerad beskrivning

This was a first-in-human (FIH), Phase 1/2, open-label, multicenter, dose escalation, and dose expansion study designed to evaluate the safety, tolerability, PK, immunogenicity, and tumor response of the investigational drug KVA12123, subsequently designated TBS-2025, alone and in combination with pembrolizumab in adults with relapsed or refractory advanced solid tumors. The study was planned to conduct in 4 planned parts: Parts A and B focus on dose escalation (single-agent and in combination), and Parts C and D focus on dose expansion (single-agent and in combination).

Parts A (single-agent KVA12123) and B (KVA12123 + pembrolizumab) allowed up to 10 dose escalation cohorts: 6 in Part A and 4 in Part B, with 1 to 6 participants per cohorts. These parts were intended to characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary tumor response, and to inform the selection of recommended phase 2 doses.

Parts C (single-agent KVA12123) and D (KVA12123 + pembrolizumab) were planned but not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern.

Studietyp

Interventionell

Inskrivning (Faktisk)

40

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Santa Monica, California, Förenta staterna, 90404
        • UCLA Health (Santa Monica Cancer Care)
    • Colorado
      • Denver, Colorado, Förenta staterna, 80218
        • Sarah Cannon Research Institute at HealthONE
    • Florida
      • Sarasota, Florida, Förenta staterna, 34232
        • Sarah Cannon Research Institute at Florida Cancer Specialists
    • Michigan
      • Ann Arbor, Michigan, Förenta staterna, 48109
        • University of Michigan
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19107
        • Thomas Jefferson University
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37203
        • Sarah Cannon Research Institute at Tennessee Oncology
    • Washington
      • Seattle, Washington, Förenta staterna, 98109
        • Fred Hutchinson Cancer Research Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria

  1. Willing and able to provide informed consent.

  2. Be at least 18 years of age at the time of consent.

  3. Has histologically or cytologically confirmed, locally advanced or metastatic solid tumor that has progressed or was non-responsive to standard of care therapy and for which no available curative therapy exists.

  4. Has expected survival ≥16 weeks.

  5. Presence of measurable disease by iRECIST.

  6. Has an ECOG performance status score of 0 or 1.

  7. Has adequate organ function within 10 days prior to the start of study treatment.

  8. Has normal thyroid function or hypothyroid with stable supplementation.

  9. Has consented to the collection of archival tissue prior to study treatment initiation.

  10. Participants with prior exposure to systemic anticancer therapy including investigational agents following a 4-week washout period are eligible. Participants with prior small molecule targeted therapy or other short half-life drugs are eligible following a 2-week washout period.

  11. Participants having prior curative radiation therapy completed 2 weeks prior to study drug administration or prior palliative radiation therapy to non-CNS disease completed at least 1 week prior to study drug administration are eligible.

  12. HIV-infected participants must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease.

  13. Participants with a history of HBV infection having durable HBsAg loss and undetectable serum HBV DNA no longer requiring treatment are eligible.

  14. Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening and participants have completed curative antiviral therapy.

  15. Post-menopausal women and surgically sterile men and women are permitted.

  16. Patients of childbearing potential are permitted to participate under the following conditions:

    1. Must have negative urine pregnancy test result within 72 hrs prior to the first dose of any study drug
    2. Must agree not to become pregnant during the study and for 120 days after the final dose of any study drug
    3. Must agree not to breastfeed or donate ova, starting at time of informed consent and continuing through 120 days after the final dose of any study drug
    4. If sexually active in a way that could lead to pregnancy, must consistently use 2 acceptable methods of birth control (contraception), at least 1 of which must be highly effective starting at time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug.
  17. Patients who can father children are permitted to participate under the following conditions:

    1. Must agree not to donate sperm starting at the time of informed consent and continuing throughout the study period and for 120 days after the final dose of any study drug
    2. If sexually active with a person of childbearing potential in a way that could lead to pregnancy, must consistently use 2 acceptable methods of birth control (contraception), at least 1 of which must be highly effective starting at the time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug
    3. If sexually active with a person who is pregnant or breastfeeding, must consistently use a condom starting at time of informed consent and continuing throughout the study and for 120 days after the final dose of any study drug.
  18. Must be willing and able to comply with the trial procedures and the follow-up schedule.

Exclusion Criteria

  1. Untreated CNS metastatic disease, leptomeningeal disease, or cord compression.
  2. Concurrent cancer other than disease under study requiring systemic treatment. Participants with basal cell or squamous cell skin cancer treated with curative intent, carcinoma in-situ of the cervix or breast treated with curative intent, RAI stage 0 Chronic Lymphocytic Leukemia, monoclonal gammopathy of undetermined significance, superficial bladder cancer or very low and low risk prostate cancer (localized Gleason score ≤ 6) under active surveillance are eligible.
  3. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
  4. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg QD of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.
  5. History of (non-infectious) pneumonitis/interstitial lung disease (ILD) that required steroids or current pneumonitis/ILD.
  6. Prior treatment with VISTA-targeted therapy.
  7. Prior history of allogeneic, solid organ or stem cell transplant, or adoptive T-cell transplant.
  8. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, LAG-3, OX 40, CD137), and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE).
  9. Active known or suspected autoimmune disease that has required systemic treatment within the past year. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  10. Prior systemic anticancer therapy, including investigational agents, within 4 weeks of treatment. Participants with prior small molecule targeted therapy or other short half-life drugs are eligible following a 2-week washout period.
  11. Has received prior radiation therapy within 2 weeks of start of study treatment or has a history of radiation pneumonitis.
  12. Has received radiation therapy to the lung that is >30 Gy within 6 months of the first dose of study treatment.
  13. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.
  14. Any requirement for daily supplemental oxygen.
  15. Any condition requiring systemic treatment with corticosteroids (>10 mg QD prednisone equivalents) or other immunosuppressive medications within 14 days before the first dose of study drug.
  16. Serious or poorly controlled cardiovascular disease.
  17. Chronic hepatitis B or C.
  18. HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
  19. Has an active infection requiring systemic therapy.
  20. Known active or latent tuberculosis.
  21. If the participant had major surgery, must have recovered adequately from the procedure and/or any complications.
  22. Toxicities arising from prior cancer therapy that have not resolved to Grade 1 or baseline.
  23. Red blood cell or platelet infusion within the preceding 2 weeks.
  24. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  25. Known hypersensitivity to any excipient contained in the drug formulation of KVA12123.
  26. Any significant history of drug allergy as assessed by the investigator.
  27. Positive urine pregnancy test within 72 hrs of study drug administration.
  28. Participants who are breastfeeding, pregnant, or planning to become pregnant from time of informed consent until at least 120 days after final dose of study drug.
  29. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study.
  30. Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  31. Inability to comply with study procedures.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: KVA12123 [TBS-2025] Monotherapy Dose Escalation

Part A will consist of dose escalation with KVA12123 [TBS-2025] administered as a single agent in participants with advanced solid tumors.

Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.

Experimentell: KVA12123 [TBS-2025] Plus Pembrolizumab Dose Escalation

Part B will consist of dose escalation with KVA12123 administered in combination with a fixed dose of pembrolizumab.

Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.

Andra namn:
  • Keytruda
Experimentell: KVA12123 [TBS-2025] Monotherapy Dose Expansion

Part C will consist of dose expansion with KVA12123 [TBS-2025] administered as a single agent at the RP2D in participants with advanced solid tumors. Part C was not initiated.

KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.

Experimentell: KVA12123 Plus Pembrolizumab Dose Expansion

Part D will consist of dose expansion with KVA12123 [TBS-2025] administered at the RP2D in combination with a fixed dose of pembrolizumab. Part D was not initiated.

KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.

Andra namn:
  • Keytruda

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Adverse Events
Tidsram: Through study completion, an average of 1 year

Type and frequency of adverse events as assessed by CTCAE v5.0.

Through study completion, an average of 1 year
AEs related to study drug
Tidsram: Through study completion, an average of 1 year

Type and frequency of treatment related adverse events as assessed by CTCAE v4.0.

Through study completion, an average of 1 year
Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)
Tidsram: Through study completion, an average of 1 year

Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD) of KVA12123 when administered alone and in combination with pembrolizumab in participants with advanced solid tumors (milligrams or milligrams/kilogram).

Through study completion, an average of 1 year

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pharmacokinetic (PK) profile of KVA12123 (Cmax)
Tidsram: Through study completion, an average of 1 year

maximum serum concentration (micrograms/milliliter [mL])

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (Cmin)
Tidsram: Through study completion, an average of 1 year

trough serum concentration (micrograms/mL)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (tmax)
Tidsram: Through study completion, an average of 1 year

time to maximum serum concentration (hours)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (AUC)
Tidsram: Through study completion, an average of 1 year

Area under the concentration-time curve (microgram*mL/hour)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (t1/2)
Tidsram: Through study completion, an average of 1 year

Elimination half life (hours)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (Vd)
Tidsram: Through study completion, an average of 1 year

Volume of distribution (milliliter or liter)

Through study completion, an average of 1 year
Pharmacokinetic (PK) profile of KVA12123 (Cl)
Tidsram: Through study completion, an average of 1 year

Clearance (mL/hour)

Through study completion, an average of 1 year
Concentration of anti-KVA12123 antibodies in serum
Tidsram: Through study completion, an average of 1 year

Change from baseline in anti-KVA12123 antibodies in serum (antibody concentration per mL)

Through study completion, an average of 1 year
Number of participants with progressive disease following treatment with KVA12123
Tidsram: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with progressive disease following treatment with KVA12123 in combination with pembrolizumab
Tidsram: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with stable disease following treatment with KVA12123
Tidsram: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with stable disease following treatment with KVA12123 plus pembrolizumab
Tidsram: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with partial response following treatment with KVA12123
Tidsram: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with partial response following treatment with KVA12123 plus pembrolizumab
Tidsram: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with complete response following treatment with KVA12123
Tidsram: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year
Number of participants with complete response following treatment with KVA12123 plus pembrolizumab
Tidsram: Through study completion, an average of 1 year

Investigator assessment of radiographic imaging according to iRECIST.

Through study completion, an average of 1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Utredare

  • Studierektor: Thierry Guillaudeux, PhD, Kineta Inc.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 mars 2023

Primärt slutförande (Faktisk)

16 oktober 2025

Avslutad studie (Faktisk)

18 december 2025

Studieregistreringsdatum

Först inskickad

9 december 2022

Först inskickad som uppfyllde QC-kriterierna

24 januari 2023

Första postat (Faktisk)

1 februari 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • VISTA-101
  • KEYNOTE-E67 (Annan identifierare: Merck, Sharp & Dohme, LLC)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera